ReachMD

Be part of the knowledge.™

Cardiology

198

LikeLikedUnlike

Episodes 1-15 of 24

- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
  Peer
- Leslie Cho, MD
  Peer
1
CME/CE
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
0.25 credits
- George Bakris, MD
  Peer
- Biff F. Palmer, MD
  Peer
1
CME/CE
RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option
RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option
0.25 credits
- Hector O. Chapa, MD
  Peer
- Marc S. Sabatine, MD, MPH
  Peer
0
CME/CE
Optimizing LDL-C Management in the Post-MI Patient
Optimizing LDL-C Management in the Post-MI Patient
0.50 credits
- Paul W. Armstrong, MD
  Peer
- Justin Ezekowitz, MD, MBBCh, MSc
  Peer
3
CME/CE
Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness
Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness
0.25 credits
- Ileana L. Piña, MD, MPH, FAHA, FACC
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
3
CME/CE
Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinicians
Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinicians
0.25 credits
- Christie M. Ballantyne, MD
  Peer
- John J. Russell, MD
  Peer
5
CME/CE
Optimizing Outcomes in Familial Hypercholesterolemia: Diagnosis, Treatment, and Management
Optimizing Outcomes in Familial Hypercholesterolemia: Diagnosis, Treatment, and Management
0.50 credits
- Michael Miller, MD, FACC, FAHA, FNLA
  Peer
- Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
  Peer
15
CME/CE
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA
0.25 credits
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
  Peer
- James A. Underberg, MD
  Peer
- Nathan D. Wong, PhD, MPH
  Peer
3
CME/CE
Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts
Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts
0.50 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Paul W. Armstrong, MD
  Peer
14
CME/CE
New Therapies Offer Improved Outcomes in HFrEF Management
New Therapies Offer Improved Outcomes in HFrEF Management
0.25 credits
- Azeem Latib, MD
  Peer
- Sarah Kohnstamm, MD, FACC
  Peer
7
CME/CE
Spotlight on New Guidelines to Identify and Manage Aortic Stenosis
Spotlight on New Guidelines to Identify and Manage Aortic Stenosis
0.50 credits
- Jay S. Giri, MD, MPH
  Peer
- Renuka Jain, MD
  Peer
6
CME/CE
New Opportunities to Manage Aortic Stenosis with TAVR
New Opportunities to Manage Aortic Stenosis with TAVR
0.50 credits
- Javed Butler, MD, MBA, MPH
  Peer
2
CME/CE
Mr. Jackson ist neu in der Stadt: Das Bewältigen von Herausforderungen bei der Optimierung der RAASi-Therapie
Mr. Jackson ist neu in der Stadt: Das Bewältigen von Herausforderungen bei der Optimierung der RAASi-Therapie
0.25 credits
- Gregory Lewis, MD
  Peer
- Michael Böhm, MD, FESC
  Peer
- Josep Comin-Colet, MD, PhD
  Peer
12
CME/CE
Clinical Implications of Managing Iron Deficiency from AFFIRM-AHF
Clinical Implications of Managing Iron Deficiency from AFFIRM-AHF
0.25 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Piotr Ponikowski, MD, PHD, FESC, FHFA
  Peer
- Gerasimos Filippatos, MD, FESC, FHFA
  Peer
6
CME/CE
AHA 2020: Neue Erkenntnisse zu Eisenmangel und Herzinsuffizienz
AHA 2020: Neue Erkenntnisse zu Eisenmangel und Herzinsuffizienz
0.25 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Piotr Ponikowski, MD, PHD, FESC, FHFA
  Peer
- Gerasimos Filippatos, MD, FESC, FHFA
  Peer
13
CME/CE
AHA 2020: New Insights on Iron Deficiency and Heart Failure
AHA 2020: New Insights on Iron Deficiency and Heart Failure
0.25 credits

Programs 7/27/21

Segment Chapters

Playlist:

Recommended